EUVIMEDEUVIMED entdecken
Crossref

Considerations for developing a health-system 503B outsourcing strategy

Gilnou Pamphile, Angela Yaniv, Samantha Burton, Christopher Boreen, Garrett Eggers

American Journal of Health-System Pharmacy · 2025

DOI: 10.1093/ajhp/zxae271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Gilnou Pamphile und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Outsourced Services, Pharmacy Service, Hospital, Drug Compounding. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To provide guidance for health systems on how to develop a strategy for utilizing 503B outsourcing facilities for sterile product preparation. Summary Health-system pharmacies face an increasingly complex set of challenges related to providing sterile products to patients. New United States Pharmacopeia <797> regulations, increasing drug shortages, and an ongoing pharmacy technician workforce shortage have made sterile compounding more difficult than ever for health-system pharmacies. Outsourcing of production to 503B outsourcing facilities is one strategy pharmacy leaders can use to help navigate these challenges. However, there are many factors to consider when deciding whether to outsource a product and which 503B vendors are safe and reliable. The Cleveland Clinic Health System (CCHS) has developed a robust internal structure to appropriately vet 503B outsourcing facilities for safety and reliability, as well as standardized criteria used to determine which products will be outsourced. This article describes the tools CCHS has used to evaluate 503B outsourcing vendors and to evaluate individual products to determine the pros and cons of outsourcing vs insourcing. Additionally, general considerations regarding outsourcing are described.

Conclusion

Outsourcing to 503B facilities can be an effective strategy for navigating sterile compounding challenges but is not without some risk. Pharmacy leaders must develop a standardized approach to thoroughly evaluate 503B vendors and products to ensure their outsourcing strategy is both safe and cost-effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Outsourced ServicesPharmacy Service, HospitalDrug CompoundingHumansSterilization

Stichwörter der Autor:innen

503B compounding facilitiesconsiderations when outsourcing pharmacy productshealth-system pharmacy serviceshospital/methods in pharmacy servicessterile products compounding facilities

Autor:innen und Institutionen

  • Cleveland Clinic, Cleveland, OH, USA.
  • Baxter Healthcare Corporation, Deerfield, IL, USA.
  • Department of Pharmaceutical Care, University of Iowa Health Care, Iowa City, IA, USA.

Zitieren

APA

Pamphile, G., Yaniv, A., Burton, S., Boreen, C., & Eggers, G. (2025). Considerations for developing a health-system 503B outsourcing strategy. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae271

Vancouver

Pamphile G, Yaniv A, Burton S, Boreen C, Eggers G. Considerations for developing a health-system 503B outsourcing strategy. American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxae271

BibTeX
@article{Pamphile2025,
  author = {Pamphile, Gilnou and Yaniv, Angela and Burton, Samantha and Boreen, Christopher and Eggers, Garrett},
  title = {Considerations for developing a health-system 503B outsourcing strategy},
  journal = {American Journal of Health-System Pharmacy},
  year = {2025},
  doi = {10.1093/ajhp/zxae271}
}
Kostenlos starten →